{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:01:43Z","timestamp":1791414103477,"version":"4.3.3"},"reference-count":24,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2003,10,1]],"date-time":"2003-10-01T00:00:00Z","timestamp":1064966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2003,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            MIC methodology was used to test the antibacterial activity of XRP 2868, a new oral combination of two semisynthetic streptogramins, RPR 132552A and RPR 202868, compared to activities of other antibacterial agents against pneumococci,\n            <jats:italic>Haemophilus influenzae<\/jats:italic>\n            , and\n            <jats:italic>Haemophilus parainfluenzae<\/jats:italic>\n            . For 261 pneumococci, XRP 2868 and pristinamycin MICs were similar, irrespective of penicillin G and erythromycin A susceptibilities (MIC at which 50% of isolates were inhibited [MIC\n            <jats:sub>50<\/jats:sub>\n            ], 0.25 \u03bcg\/ml; MIC\n            <jats:sub>90<\/jats:sub>\n            , 0.5 \u03bcg\/ml), while quinupristin\/dalfopristin had MICs which were 1 to 2 dilutions higher. Single components of both XRP 2868 and quinupristin\/dalfopristin had higher MICs. Erythromycin A, azithromycin, clarithromycin, and clindamycin MICs were higher for penicillin G-intermediate and -resistant than -susceptible pneumococci. Against 150\n            <jats:italic>H. influenzae<\/jats:italic>\n            strains, all compounds tested had unimodal MIC distributions. XRP 2868 had an overall MIC\n            <jats:sub>50<\/jats:sub>\n            of 0.25 \u03bcg\/ml and an MIC\n            <jats:sub>90<\/jats:sub>\n            of 1.0 \u03bcg\/ml, with no differences between \u03b2-lactamase-positive, \u03b2-lactamase-negative, and \u03b2-lactamase-negative ampicillin-resistant strains. Of note was the similarly low activity of one of its components, RPR 132552A. Pristinamycin and quinupristin\/dalfopristin had MICs of 0.125 to 8.0 \u03bcg\/ml; quinupristin alone had MICs of 8.0 to &gt;64.0 \u03bcg\/ml, and dalfopristin had MICs of 1.0 to &gt;64.0 \u03bcg\/ml. Erythromycin A, azithromycin, and clarithromycin had modal MICs of 4.0, 1.0, and 8.0 \u03bcg\/ml, respectively. MICs of all compounds against\n            <jats:italic>H. parainfluenzae<\/jats:italic>\n            were 1 to 2 dilutions higher than against\n            <jats:italic>H. influenzae<\/jats:italic>\n            . XRP 2868 showed potent activity against pneumococci and\n            <jats:italic>Haemophilus<\/jats:italic>\n            strains irrespective of their susceptibility to other agents.\n          <\/jats:p>","DOI":"10.1128\/aac.47.10.3270-3274.2003","type":"journal-article","created":{"date-parts":[[2003,9,23]],"date-time":"2003-09-23T22:25:36Z","timestamp":1064355936000},"page":"3270-3274","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":26,"title":["Activities of a New Oral Streptogramin, XRP 2868, Compared to Those of Other Agents against\n            <i>Streptococcus pneumoniae<\/i>\n            and\n            <i>Haemophilus<\/i>\n            Species"],"prefix":"10.1128","volume":"47","author":[{"given":"Glenn A.","family":"Pankuch","sequence":"first","affiliation":[{"name":"Department of Pathology, Hershey Medical Center, Hershey, Pennsylvania 17033"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda M.","family":"Kelly","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hershey Medical Center, Hershey, Pennsylvania 17033"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gengrong","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hershey Medical Center, Hershey, Pennsylvania 17033"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Bryskier","sequence":"additional","affiliation":[{"name":"Aventis Pharma, Romainville, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Couturier","sequence":"additional","affiliation":[{"name":"Aventis Pharma, Romainville, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Case Western Reserve University, Cleveland, Ohio 44106"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Appelbaum","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hershey Medical Center, Hershey, Pennsylvania 17033"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.10.2149"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/15.1.77"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199509000-00005"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03510470035031"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-0691.2000.00185.x"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.1.67-72.2001"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199408113310607"},{"key":"e_1_3_2_9_2","first-page":"197","volume":"17","year":"1998","unstructured":"Fuchs, P., A. Barry, S. Brown, et al. 1998. Provisional quality control parameters and interpretive criteria for testing susceptibility of Streptococcus pneumoniae and Haemophilus influenzae to quinupristin\/dalfopristin (RP 59500). Eur. J. Clin. Microbiol. Infect. Dis.17:197-201.","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/15.1.119"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00013542-199504000-00001"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.8.1901"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/42.6.711"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.9.2963-2968.2002"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/48.suppl_2.9"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.1999.tb00178.x"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/15.1.112"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.11.3242-3245.2001"},{"key":"e_1_3_2_19_2","unstructured":"National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically 5th ed.; approved standard. NCCLS publication no. M7-A5. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.9.2065"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.14.2.336-363.2001"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.4.856"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.2.481"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.6.1693-1699.2001"},{"key":"e_1_3_2_25_2","first-page":"214","volume":"14","year":"1992","unstructured":"Zeckel, M. L., K. D. Jacobson, F. J. Guerra, D. G. Therasse, and D. Farlow. 1992. Loracarbef (LY 163892) versus amoxicillin\/clavulanate in the treatment of acute exacerbations of chronic bronchitis. Clin. Ther.14:214-229.","journal-title":"Clin. Ther."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.47.10.3270-3274.2003","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.47.10.3270-3274.2003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T17:52:33Z","timestamp":1645465953000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.47.10.3270-3274.2003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2003,10]]}},"alternative-id":["10.1128\/AAC.47.10.3270-3274.2003"],"URL":"https:\/\/doi.org\/10.1128\/aac.47.10.3270-3274.2003","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,10]]},"assertion":[{"value":"2003-06-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-07-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-10-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}